Literature DB >> 14250649

OCULAR TOXICITY WITH SPARSOMYCIN (NSC-59729) IN A PHASE I STUDY: A PRELIMINARY REPORT.

H P CLOSE, J R MCFARLANE.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASE; BLOOD; CLINICAL RESEARCH; NEOPLASM THERAPY; PATHOLOGY; SCOTOMA; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1964        PMID： 14250649

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

1.  Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin.

Authors:  R J Ash; L D Fite; D W Beight; G A Flynn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

2.  In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.

Authors:  H H Fiebig; D P Berger; K Köpping; H C Ottenheijm; Z Zylicz
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; M Garzotto; T B Vree; E van der Kleijn; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

4.  Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; P Fernandez del Moral; H van Rennes; J M Wessels; B Winograd; E van der Kleijn; T B Vree; U van Haelst; L A van den Broek
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.

Authors:  Z Zylicz; D J Wagener; H van Rennes; E van der Kleijn; P Lelieveld; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.